Clinical Trials
85 trialsOrgan Preservation in Early Rectal Cancer Patients
Fox Chase Cancer Center
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
TNT Esophagus
Duke University
SEVILLA
UNICANCER
CLEAR-04
Fudan University
CLEAR-02
Fudan University
GRACIE
UNICANCER
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Third Affiliated Hospital, Sun Yat-Sen University
FUDOSE
UNICANCER
PROTECT
Centre Oscar Lambret
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
PANTHER
Weill Medical College of Cornell University
ONTOP
Shanghai Pudong Hospital
SAMCO
Federation Francophone de Cancerologie Digestive
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
University of Campania Luigi Vanvitelli
COSENSE-1
St. Olavs Hospital
A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
SED-RO-ICC
Shanghai Zhongshan Hospital
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
CLavSyn
Centre Hospitalier Universitaire de Besancon
COLORE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
University of Rochester
LOGICAN
UNICANCER
A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Fudan University
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
Tang-Du Hospital
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Henry Ford Health System
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
INTERACT-II
Catharina Ziekenhuis Eindhoven
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
China Medical University, China
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Tianjin Medical University Cancer Institute and Hospital
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
Tianjin Medical University Cancer Institute and Hospital
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology